Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta
Trial details
- Registry ID
- NCT07108153
- Phase
- Phase 2
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to TrikaftaNCT07108153 | SION | Phase 2 | Completed | 2026-06-25Actual |
NCT07108153 · Sionna Therapeutics Inc.
Estimated
Actual
16 participants (planned)
15 participants (actual)
Estimated
Actual
Jul 2026
25 Jun 2026
Active not recruiting
Completed
NCT07108153 · Sionna Therapeutics Inc.
Recruiting
Active not recruiting
NCT07108153 · Sionna Therapeutics Inc.
Not yet recruiting
Recruiting